Please select the option that best describes you:
What would be your first line treatment option for a symptomatic patient with grade 3 well differentiated GI neuroendocrine tumor?
Would the presence of peritoneal carcinomatosis change your treatment strategy? If Ki-67 <50%, would you avoid platinum based cytotoxics?
Answer from: Medical Oncologist at Academic Institution
This would be a somewhat unusual scenario in small bowel NETs as they are uncommonly grade 3 (G3). That said, we and others, have increasingly been seeing well differentiated G3 NETs of small bowel origin, usually late in the disease course and in repeat biopsies. Most WD G3 NETs are of pancreatic o...
Sign in or Register to read more